Pathik Amin, OD, FAAO, gave a presentation to the optometry cohort at the conference on glaucoma management, focusing on surgical options and recent advancements. McCabe, MD, presented alongside P.

Anita Shiva | Authors | Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial. At Glaucoma 360 2025, ...

Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies." Kevin Chan, OD, MS, discusses an AAOpt 2026 ...

From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry. Want more ...

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular ...

Gromacki said that, at the time of the discussion, there were no FDA-approved drug-eluting lenses in the US. She mentioned ...

The approval gives eye care providers a new pharmacologic option for adults with presbyopia. Phentolamine is a non-selective alpha-1 and alpha-2 adrenergic antagonist, and the drug reduces pupil ...

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication. The FDA has approved Enspryng (satralizumab, ...